Clinical analysis of anti-sideroflexin 3-autoantibody as a novel tumor marker for oral squamous cell carcinoma.
| Project/Area Number |
20791529
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
MURASE Ryuichi Ehime University, 医学部・附属病院, 医員 (70452696)
|
|---|
| Research Collaborator |
SUMIDA Tomoki 愛媛大学, 大学院・医学系研究科, 大学院生 (50314951)
AMANO Yoshiyuki 三洋化成工業医療産業, 分社長
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 口腔扁平上皮癌 / 腫瘍マーカー / 早期診断 / フォローアップマーカー / 抗体価測定キット / 口腔癌 / プロテオミクス / 血清 |
|---|
| Research Abstract |
The purpose of this study is to establish a tumor marker that can be applied for the early detection and follow-up oral cancer patients. Employing the proteomic approach using MALDI TOF-MS, 2-DE, patient's sera and culturing cell lines, a mitochondrial membrane protein, sideroflexin 3 (SFXN3), was identified. The serum anti-SFXN3-autoAb levels elevated in patients with oral squamous cell carcinoma significantly: with 72% sensitivity and 81% specificity against control samples. Changes in serum anti-SFXN3-autoAb levels after therapy correlated with the clinical tumor burden.
|
Report
(3 results)
Research Products
(6 results)
